% IMPORTANT: The following is UTF-8 encoded. This means that in the presence % of non-ASCII characters, it will not work with BibTeX 0.99 or older. % Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or % “biber”. @ARTICLE{Stichel:137576, author = {D. Stichel$^*$ and A. Ebrahimi$^*$ and D. Reuss$^*$ and D. Schrimpf$^*$ and T. Ono and M. Shirahata and G. Reifenberger$^*$ and M. Weller and D. Hänggi and W. Wick$^*$ and C. Herold-Mende and M. Westphal and S. Brandner and S. Pfister$^*$ and D. Capper$^*$ and F. Sahm$^*$ and A. von Deimling$^*$}, title = {{D}istribution of {EGFR} amplification, combined chromosome 7 gain and chromosome 10 loss, and {TERT} promoter mutation in brain tumors and their potential for the reclassification of {IDH}wt astrocytoma to glioblastoma.}, journal = {Acta neuropathologica}, volume = {136}, number = {5}, issn = {1432-0533}, address = {Berlin}, publisher = {Springer}, reportid = {DKFZ-2018-01456}, pages = {793-803}, year = {2018}, abstract = {EGFR amplification (EGFRamp), the combination of gain of chromosome 7 and loss of chromosome 10 (7+/10-), and TERT promoter mutation (pTERTmut) are alterations frequently observed in adult IDH-wild-type (IDHwt) glioblastoma (GBM). In the absence of endothelial proliferation and/or necrosis, these alterations currently are considered to serve as a surrogate for upgrading IDHwt diffuse or anaplastic astrocytoma to GBM. Here, we set out to determine the distribution of EGFRamp, 7+/10-, and pTERTmut by analyzing high-resolution copy-number profiles and next-generation sequencing data of primary brain tumors. In addition, we addressed the question whether combinations of partial gains on chromosome 7 and partial losses on chromosome 10 exhibited a diagnostic and prognostic value similar to that of complete 7+/10-. Several such combinations proved relevant and were combined as the 7/10 signature. Our results demonstrate that EGFRamp and the 7/10 signature are closely associated with IDHwt GBM. In contrast, pTERTmut is less specific for IDHwt GBM. We conclude that, in the absence of endothelial proliferation and/or necrosis, the detection of EGFRamp is a very strong surrogate marker for the diagnosis of GBM in IDHwt diffuse astrocytic tumors. The 7/10 signature is also a strong surrogate marker. However, care should be taken to exclude pleomorphic xanthoastrocytoma. pTERTmut is less restricted to this entity and needs companion analysis by other molecular markers to serve as a surrogate for diagnosing IDHwt GBM. A combination of any two of EGFRamp, the 7/10 signature and pTERTmut, is highly specific for IDHwt GBM and the combination of all three alterations is frequent and exclusively seen in IDHwt GBM.}, cin = {G380 / G370 / B062 / L101 / L201 / L401}, ddc = {610}, cid = {I:(DE-He78)G380-20160331 / I:(DE-He78)G370-20160331 / I:(DE-He78)B062-20160331 / I:(DE-He78)L101-20160331 / I:(DE-He78)L201-20160331 / I:(DE-He78)L401-20160331}, pnm = {317 - Translational cancer research (POF3-317)}, pid = {G:(DE-HGF)POF3-317}, typ = {PUB:(DE-HGF)16}, pubmed = {pmid:30187121}, doi = {10.1007/s00401-018-1905-0}, url = {https://inrepo02.dkfz.de/record/137576}, }